Here are five highlights:
1. CINGAL is a medical device used to treat pain associated with osteoarthritis of the knee.
2. CINGAL is Anika’s third-generation viscosupplement, following the company’s ORTHOVISC and MONOVISC products to treat pain associated with osteoarthritis of the knee.
3. Anika previously achieved approval of CINGAL in Canada and is currently working with its distribution partner to finalize the commercial launch of the product in the second quarter of 2016. The company also continues to pursue regulatory approval of the product in the United States.
4. CINGAL is administered via injection into the knee by a physician.
5. Anika Therapeutics is a global, integrated orthopedic medicines company based in Bedford, Mass.
More articles on devices and implants:
NuVasive’s short interest jumps by 26.2%: 4 things to know
Drawing stem cells on damaged cartilage: 6 observations on the new biopen
Segall Bryant Hamill owns $52.5M stake in Orthofix International — 4 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
